

acta
endocrino
logica

Volume 128

January–June 1993

J Med 52 113

*128
1993*

+ Suppl.

CHIEF EDITOR

A. G. BURGER

EDITORS

F. BIDLINGMAIER

H. DREXHAGE

S. EDEN

J. FABER

E. HAUG

I. HUHTANIEMI

Author index, Vol. 128

- Aanestad M 361
 Aceto Jr T 345
 Adamson UCK 95
 Ambrogio C 150
 Andersen PH 251
 Andréasson K 95
 Arntz H-R 202
 Asakawa K 101
 Asem EK 178
 Attanasio R 389

 Baba H 367
 Badskjær J 297
 Bahn RS 41
 Bähr V 120
 Bak J 251
 Bakke S 301
 Balducci R 19
 Bang P 397
 Barinov VV 543
 Bartke A 74
 Bassalyk LS 543
 Bauman M 325
 Baxter RC 101
 Beckmann MW 161
 Bendtson I 109
 Bengtsson B-Å 418
 Benker G 51
 Benraad TJ 428
 Bianchi P 19
 Bidlingmaier F 15, 24
 Binder C 109
 Birman P 9
 Bjoro T 301, 308, 361
 Blum WF 313, 397, 513
 Blumberg-Tick J 351
 Bogner U 202
 Borm GF 428
 Boscaro M 293
 Boscherini B 19
 Bouchard P 351
 Brailly S 351
 Breckwoltd M 161
 Breton R 563
 Brinsmead MW 339
 Brixen K 263
 Brownell J 301
 Bucht E 35, 423
 Bugalho MJGM 289
 Bullen BA 325
 Burger AG 451
 Busnardo B 293
 Bussi AR 131

 Campos JAM 289
 Canale G 439
 Cañizo FJ 197
 Carstensen H 221
 Cassiède P 243
 Cassiman JJ 334
 Ceccatelli S 485
 Chan E-C 339
 Chanson P 351

 Chapman M 259
 Charles P 263
 Cheng B-H 385
 Chiang MH 65
 Chihara K 367
 Chiodini PG 389
 Chiovata L 439
 Christiansen JS 513
 Christie HL 173
 Christol R 9
 Clode AL 289
 Combarnous Y 555
 Conover CA 140
 Corran P 443
 Cozzi R 389
 Crook D 259
 Crowley WR 184
 Cuber JC 243
 Cubis J 339

 da Silva CG 289
 D'Alessandro V 150
 Dahl R 263
 Dallabonzana D 389
 Das SC 116
 De Gennaro T 150
 Degerblad M 397
 de la Llosa-Hermier MP 478
 de Zegher F 334
 Dereser MM 161
 Devriendt K 334
 Deyssig R 313
 Divertie GD 140
 Djøseland O 301
 Doga M 131
 Dorfmueller S 120
 Ducassou D 243
 Duranteau L 351

 Eguchi K 215
 Eikvar L 568
 Eliasson M 35
 Emrich D 51
 Endo T 126
 Enzweiler C 15
 Erfurth EMT 29
 Eskild W 568
 Esquifino AI 74
 Evans WJ 325

 Falcone V 439
 Fallo F 293
 Farkas G 549
 Fava GA 293
 Fehr S 411
 Fernandez C 478
 Flecken U 161
 Foresta C 274
 Freeman EW 536
 Frey HH 308
 Frisch H 313
 Frölich M 319
 Fujita T 367

 Fujiwara M 394
 Fukase M 367
 Fukuda T 215
 Furukawa K 88

 Gaines-Das RE 443
 Galloë AM 297
 Garibaldi LR 345
 Gibb W 563
 Girard F 9
 Girelli ME 293
 Giustina A 131
 Gomes da Silva C 289
 Grino M 466
 Grosvenor CE 184
 Guglielmi R 19
 Guillou F 555

 Habert R 268
 Hägg E 35
 Hall K 81, 397
 Hall P 230
 Halse J 301
 Hamamoto K 394
 Hansen E 301
 Hansson V 568
 Harlin CA 136
 Hashimoto K 503
 Haug E 361
 Hawkins F 197
 Hayashi H 379
 Heikinheimo O 459
 Henley K 325
 Henson B 136
 Hermier C 478
 Hermus AR 428
 Heufelder AE 41
 Hilsted J 221
 Hizuka N 101
 Ho M-L 385
 Hochberg Z 56
 Hocker B 120
 Holm L-E 230
 Holman SR 101
 Holst JJ 207
 Horn N 513
 Hsu C 385
 Hulting AL 423
 Hurt D 339

 Ida H 215
 Ikeda H 69, 126
 Inada C 379
 Iranmanesh A 521
 Isaksson M 81
 Isberg B 423
 Ishida H 69
 Ishikawa N 215
 Ishimura Y 235
 Isichei UP 116
 Isojima S 355
 Ito K 215
 Itoi K 192

 Jakobsson K-E 418
 Jervel J 301
 Jockenhövel F 281
 Johansen E 308
 Jones TH 405
 Jørgensen JOL 513
 Justice SK 405

 Kacsóh B 184
 Kageyama J 503
 Kajiyama M 394
 Kanety H 144
 Karasik A 144
 Karlsson FA 156
 Karlsson R 35
 Kasumi H 355
 Kawabe Y 215
 Kawakami A 215
 Kelestimur F 99
 Kelley KM 65
 Kennedy RL 405
 Kimura T 367
 Klinger B 144
 Klingmüller D 15, 24
 Kloppenborg PW 428
 Koch C 207
 Koh G 69
 Kokawa N 88
 Komori S 355
 Koppeschaar HPF 319
 Koppold A 373
 Krasil'nikov MA 543
 Kurose T 69
 Kuzmina ZV 543
 Kvistborg A 301

 Ladefoged SD 297
 Landin K 418
 Lannig S 207
 Laron Z 144
 Laurent-Cadoret V 555
 Lavielle R 251
 Le Bouc Y 9
 Lechner K 433
 Lee J-N 385
 Lee PDK 140
 Leiper AD 508
 Letyagin VP 543
 Lewin T 339
 Li PHS 385
 Liang H 451
 Licini M 131
 Limone P 150
 Lindgren BF 81
 Lins P-ES 95
 List S 221
 Liu D 95
 Luzzi A 389
 Lizarralde G 521
 Llosa-Hermier MP de la 478
 Lubetzki J 351
 Lüdecke DK 411
 Lundblad D 35

- Lundell G 230
 Lundin S 29
- Maccherini D 439
 Macdonald IA 95
 Mandahl A 156
 Mangiantini A 19
 Maor G 56
 Martal J 478
 Maruo T 225
 Marynen P 334
 Massa G 334
 Matsuo H 225
 McArthur JW 325
 Medina E 289
 Mehlretter G 433
 Meinders AE 319
 Mercado-Asis LB 529
 Minot AP 243
 Mioni R 274
 Miura K 529
 Miyagawa S 394
 Mochizuki M 225
 Molinatti GM 150
 Møller J 513
 Møller N 513
 Moreira-Andres MN 197
 Mori A 529
 Morin O 451
 Mouri T 192
 Müller OA 433
 Murakami O 192
 Murase H 529
 Murata K 225
- Nagataki S 215
 Nakajima K 367
 Nakamoto C 367
 Nakano R 88
 Nakashima M 215
 Nemezc G 178
 Nerup J 207
 Ni H 529
 Nicoll CS 65
 Nielsen HK 263
 Nieschlag E 281
 Nishi Y 394
 Nishioka T 503
 Nonaka K 379
 Nordin H 297
 Numata Y 503
 Nunes JFM 289
 Nyman T 168
- Oelkers W 120
 Ogasa T 503
 Ogishima T 235
 Ohmori M 126
 Ohneda M 192
 Okamoto Y 69
 Olbricht T 51
 Oliver C 466
 Onaya T 126
 Opp (Meyers) JS 184
 Oppizzi G 389
 Orazzo C 485
 Orlandi P 389
 Ørskov C 207
 Otabe S 379
 Ozawa Y 493
- Pacini F 439
 Parker CR Jr 136
 Pedersen O 251
 Pedersen B 263
 Pehrson J 325
 Pekonen F 168
 Périn I 9
 Peters H 202
 Petruson B 418
 Pholséna M 9
 Pickerill AP 499
 Pieters GF 428
 Pijl H 319
 Pinchera A 439
 Pinessi L 150
 Plowman PN 508
 Price A 405
 Priou A 466
- Quade A 24
- Raeside JI 173, 549
 Rahn M 24
 Rainero I 150
 Ranke MB 513
 Rasmussen MH 221
 Raue F 373
 Redei E 536
 Reichardt B 433
 Reinwein D 51
 Richelsen B 251
 Rjosk HK 433
 Roder ME 207
 Roger P 243
 Rosenfalck AM 109
 Røtnes JS 361
 Rousseau E 9
- Ruf W 373
 Rymer J 259
- Saeger W 411
 Sakai M 215
 Sakakibara S 367
 Sakito S 215
 Sand O 361
 Sandroock D 51
 Saruta T 235
 Schaison G 351
 Schepke M 15
 Schettino M 131
 Schleusener H 202
 Schmitz O 251
 Schneider H-G 373
 Schopohl J 433
 Schwander J 397
 Schwartz TW 221
 Schwarzenberger F 173
 Schweikert H-U 24
 Seino Y 69
 Shatskaya VA 543
 Shibata H 235
 Shima H 355
 Shimada T 529
 Shishiba Y 493
 Sidhu M 259
 Silbergeld A 144
 Silbermann M 56
 Simoni M 281
 Sjöberg HE 423
 Skrinar GS 325
 Smals AG 428
 Smith R 339
 Sobrinho LG 289
 Sone M 192
 Sonino N 293
 Sørensen NS 251
 Spitz IM 459
 Stanhope R 508
 Stern I 81
 Stevenson JC 259
 Strada S 389
 Suemaru S 503
 Suzuki H 235
 Szary A 74
- Tabarin A 243
 Takahashi K 192
 Takane N 379
 Takano K 101
 Takeshita N 69
 Tallen G 411
- Tandon N 499
 Taskén AA 568
 Terada K 215
 Thomas G 351
 Thomas BC 508
 Thorén M 397
 Thornton K 339
 Thorsteinsson B 207
 Toole GS 173
 Torjesen PA 308, 361
 Tørring O 423
 Toscano V 19
 Totsune K 192
 Tsuji K 69
 Tucker JM 136
 Turnbull BA 325
 Turner A 325
 Turter A 308
- Uhlig H 411
- Van den Bergh H 334
 Vanderschueren-Lodeweyckx M 334
 Veldhuis JD 521
 Verhofstad AA 428
 Villanua MA 74
 Vinge E 29
- Wade CE 459
 Waldhör T 313
 Watson PF 499
 Weber C 345
 Weetman AP 499
 Wenzel BE 41
 Wieacker P 161
 Wilkinson CR 549
 Willekens FLA 319
 Winkler CL 136
 Winsa B 156
 Woodward CJH 473
- Yamada K 379
 Yamamoto T 69
 Yamasaki N 355
 Yamoto M 88
 Yasuda K 529
 Yoshinaga K 192
 Yu JY-L 385
- Zanelli JM 443
 Zhang H-P 339
 Ziegler R 373

Keyword index, Vol. 128

- α -melanocyte-stimulating hormone 150
 α_2 -adrenergic system 184
- β -adrenergic receptors 150
 β -endorphin 325, 339, 521
- γ -carboxyglutamic acid-containing protein 69
 γ -interferon 405
- ^{131}I treatment 230
5 alpha reductase 161
- achondroplasia 394
acromegaly 9, 24, 131, 389, 418
ACTH 29, 120, 192, 289, 459, 521, 536
adenosine 568
adenosine triphosphatase 29
adenyl cyclase 568
adrenal 521
adrenal micronodular hyperplasia 120
adrenal tumour 235
adrenalectomy 473
adrenaline 95, 109
adrenergic beta blockers 297
adrenergic system 150
aldosterone 529
alkaline phosphatase 367
amnion 563
androgen receptor (AR) 355
annexin 563
ANP 274
anti-TSH receptor antibody 126
antipituitary antibodies 493
arachidonic acid 478, 563
arginine vasopressin 466
arterial and arterialized venous blood 95
athletes 313, 325
autoimmune thyroiditis 493
autonomic neuropathy 221
autonomous adenoma 51
- beclomethasone dipropionate 263
behavioural symptoms 536
binding protein 168
bioactive FSH 281
birth 173
blood pressure 418
body composition 313, 473
bone marrow transplantation 508
bone densitometry 423
breast cancer 543
bromocriptine 131, 389, 423
- C-peptide 207
calcitonins 35, 423, 443
calcitonin receptor 373
calcium channel blockers 297
calcium ion 274
calcium clamp 423
cAMP 361, 568
cAMP accumulation 373
cAMP-dependent protein kinase isozymes 555
carcinoid 192
- cartilage 56, 65
CCK-8 221
ceruletide 221
Cetrorelix 15
chronic renal failure 503
circadian rhythm 263
clonidine 184
complete androgen insensitivity syndrome (CAIS) 355
corticosteroid 136
corticotrope 521
corticotropin-releasing hormone 192, 339
cortisol 29, 109, 120, 140, 339, 397, 459, 521, 536
counterregulatory hormones 95
CRH 289, 485, 503
Cushing 192
Cushing's syndrome 120, 235, 289, 397, 428
CV 205-502 301, 389
cyclical Cushing's syndrome 428
cystic fibrosis 207
cytochrome P-450 235
- deconvolution 521
deiodinase 451
deoxycorticosterone 235
des-(1-3)IGF-I 81
development 268
dexamethasone 29
dexfenfluramine 251
diabetes mellitus 109, 221
digoxin 29
dimethyl urea 379
dimethyl sulfoxide 379
dogs 459
dopamine 131
dopamine agonist 301
dwarf mice 74
- eicosanoids 478
ELISA 126
endocrine ophthalmopathy 156
endocrine secretion 508
endogenous opioid peptides 325
endothelin 215
endothelin-1 192
enkephalin 485
epidermal growth factor 225, 361
estradiol 433, 543
estrogens 173, 334
estrogen secretion 549
- fatty acid binding protein 178
fetal testes 549
fetal adrenal 136
feto-maternal thyroid functions 116
fetus 268
fluoxetine 319
follicle-stimulating hormone 555
follicular development 178
follicular fluid 88, 433
free radical 379
free radical scavenger 379
FSH 15, 568
FSH heterogeneity 281

- galanin 131
gastric inhibitory polypeptide 207
gene polymorphism 499
genital skin 161
GH 19, 24, 109, 197, 289, 334, 389
GH-deficiency 24, 197
glucagon 95, 109, 207, 568
glucagon-like peptide 207
glucocorticoids 140, 563
glucocorticosteroids 263
glucose 418
glucose clamps 513
glucose metabolism 251
glucose tolerance 207
GnRH 385
GnRH antagonist 15
GnRH therapy 351
gonadectomy 473
gonadotropins 345
gonadotropin-releasing hormone-agonist 345
granulosa cells 178
Graves' disease 41, 126, 156, 215, 293, 499
growth 65
growth hormone 9, 131, 184, 313, 394, 405, 411, 418, 513
growth hormone deficiency 513
growth hormone-releasing hormone 131
growth-promoting factor 215
- Hashimoto's disease 126, 215
hCG 19
heat shock 41
hemochromatosis 351
hemodialysis 503
Hep G2 cells 81
heteronuclear ribonucleic acid 466
high density lipoproteins 259
homologous desensitization 373
hormone replacement therapy 259
HPA axis 521
hPL 65
human 443
human mononuclear leucocyte 529
human β -chorionic gonadotropin 411
human obesity 251
hypercortisolism 428
hyperlipoproteinaemia 202
hyperprolactinemia 308, 423
hyperthyroidism 51, 230, 297
hypoglycaemia 95, 109, 521
hypogonadism 351
hypoinsulinemia 140
hypophysectomy 473
hypopituitarism 19, 24, 493
hypothalamic-pituitary-adrenal disorders 503
hypothyroidism subclinical 202
- IGF 168
IGF binding protein-3 101, 104
IGF-I 56, 144, 313, 397, 423
IGF-II 397
IGFBP 168
IGFBP-1 140, 397
IGFBP-2 397
IGFBP-3 313, 397
immunohistochemistry 411
immunoreactive FSH 281
inhibin 433
inhibitor of monodeiodination 451
in situ hybridization 411, 466, 485
insulin 81, 95, 207, 418
insulin-like growth factors 81, 513
insulin-like growth factor-I 101
insulin-like growth factor binding proteins 81, 513
insulin-like 168
interferon- γ 379
interleukin 1 215, 405
interleukin-6 405
international standards 443
intracellular concentration of free calcium 361
in vitro 56
in vitro fertilization 433
iodine deficiency 116
islet cell 379
isoelectrofocusing 281
isoproterenol 568
- L-thyroxine treatment 202
Laron-type dwarfism 144
Leydig cell 268, 274
LH 15
LH pulsatility 325, 351
life events 293
lipid metabolism 251
lipocortin 563
lipoprotein Lp(a) 259
lordosis 385
luteinizing hormone 88, 268
luteinizing hormone binding inhibitor 88
lymphocyte 168
lymphocytic hypophysitis 493
lymphoid organs 74
- macroprolactinomas 301
male pig 173
mandible 56
messenger ribonucleic acid 451
methyl xanthines 568
metoclopramide 308
MHC antigen 379
mineralocorticoid receptor 529
monodeiodination 451
mood 536
mortality 230
mouse 56
muscle strength 313
- NAD 379
nalmefene 325
neonatal rat 184
neuropeptide Y 192
neuropeptide Y-like immunoreactivity 243
neurotensin 485
NMDA 385
non-insulin-dependent diabetes 69
non-responders 459
non-toxic nodular goiter 439
noradrenaline 95, 109
normal subjects 263
nucleotide substitution 355
nursing 184
- obesity 319
oligo-amenorrhoea 325
ontogenesis 549
ophthalmopathy 41
osteoblasts 367
osteocalcin 263
ovine 478
- pancreatic clamp 140
pancreatic polypeptide 207, 221
parathyroid hormone 367

- parathyroid hormone fragments 367
 paraventricular nucleus 466
 PCR 168
 pertussis toxin 405
 pharmacokinetics 459
 pheochromocytoma 243
 phosphoinositide 361
 phospholipid turnover 543
 pituitary 281
 pituitary adenoma 289, 405, 411
 pituitary cells 361
 pituitary hormones 319
 pituitary microadenoma 120
 placenta 225, 478
 plasma androgens 173
 polymerase chain reaction (PCR) 355
 porcine 549
 potassium 29, 35, 418
 precocious puberty 345
 pregnancy 136, 339
 pregnancy zone protein 334
 premenstrual syndrome 536
 primary aldosteronism 235
 PRL 361
 progestagens 259
 progesterone 433, 478, 543
 proinsulin 207
 prolactin 29, 308, 411, 423
 prostaglandins 405, 563
 protein kinase C 568
 PTH 35
 pubertal maturation 508
 puberty 173
- rats 69
 regulation 308
 releasing hormones 319
 respiratory acidosis 136
 responder 459
 rT₃ 451
 RU 486 and metabolites 459
- salivary cortisol 428
Salmonella bacteremia 439
Salmonella brandenburg 439
 secretin 221
 serotonin 319
 Sertoli cell 555
 sex hormone binding globulin 35
- short stature 197
 single fraction and fractionated total body irradiation 508
 skeletal muscle 418
 smokeless tobacco 35
 smoking 35, 156
 snuff 35
 sodium 29, 35, 418
 somatostatin 131
 standard preparation 281
 steroid hormones 35
 steroidogenesis 88, 178, 274
 steroids 161
 stress 293, 466, 521
 suckling behaviour 184
 suppression of testosterone 15
 suppurative thyroiditis 439
 systolic time interval 297
- T cell receptor 499
 T₃ 116, 451
 T₄ 451
 T47D cells 373
 tamoxifen 543
 testicular steroidogenesis 19
 testis 268
 testosterone 268, 473
 thelarche 345
 thermolability 355
 thymostimulin 74
 thyroglobulin antibodies 499
 thyroid 51
 thyroid hormone 225
 thyroid epithelial cells 215
 thyrotropin 29
 tibolone 259
 tissue plasminogen activator 555
 TPA 568
 TRH 485
 tumor necrosis factor- α 379, 405
 Turner syndrome 334
- up-regulation 529
 urinary GH 197
 urinary cortisol 428
 uterine carcinoma 543
- vasopressin 29
 yohimbine 184

Contents, Vol. 128

<i>Instructions to Authors</i>	3	<i>Nobuyoshi Kokawa, Mareo Yamoto, Kenichi Furukawa and Ryosuke Nakano</i>	
<i>Editorial</i>	7	Biological activity of partially purified low molecular weight luteinizing hormone binding inhibitor in porcine follicular fluids	88
<i>Maryse Pholséna, Yves Le Bouc, Elisabeth Rousseau, Rémy Christol, Pascal Birman, Laurence Périn and François Girard</i>		<i>Dating Liu, Karin Andréasson, Per-Eric S Lins, Ulf CK Adamson and Ian A Macdonald</i>	
Evaluation of acromegaly by measurement of 24-hourly urinary growth hormone excretion	9	Adrenaline and noradrenaline responses during insulin-induced hypoglycaemia in man: should the hormone levels be measured in arterialized venous blood?	95
<i>D Klingmüller, M Schepke, C Enzweiler and F Bidlingmaier</i>		<i>Robert C Baxter, Naomi Hizuka, Kazue Takano, Sara R Holman and Kumiko Asakawa</i>	
Hormonal responses to the new potent GnRH antagonist Cetrorelix	15	Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-1	101
<i>Rina Balducci, Vincenzo Toscano, Adele Mangiantini, Patrizia Bianchi, Rinaldo Guglielmi and Brunetto Boscherini</i>		<i>Inger Bendtson, Anne Mette Rosenfalck and Christian Binder</i>	
The effect of growth hormone administration on testicular response during gonadotropin therapy in subjects with combined gonadotropin and growth hormone deficiencies	19	Nocturnal versus diurnal hormonal counterregulation to hypoglycemia in Type 1 (insulin-dependent) diabetic patients	109
<i>Annegret Quade, Michael Rahn, Hans-Udo Schweikert, Frank Bidlingmaier and Dietrich Klingmüller</i>		<i>SC Das and UP Isichei</i>	
Urinary excretion of GH in healthy individuals and patients with acromegaly, hypopituitarism and dwarfism	24	The "feto-maternal" thyroid function interrelationships in an iodine deficient region in Africa - the role of T ₃ in possible fetal defence	116
<i>Ellen Vinge, Eva Marie T Erfurth and Stefan Lundin</i>		<i>Berthold Hocher, Volker Bähr, Severin Dorfmueller and Wolfgang Oelkers</i>	
Effects of adrenal function tests on the levels of endogenous digitalis-like substances and some pituitary hormones	29	Hypercortisolism with non-pigmented micronodular adrenal hyperplasia: transition from pituitary-dependent to adrenal-dependent Cushing's syndrome	120
<i>Mats Eliasson, Erik Hägg, Dan Lundblad, Roger Karlsson and Elisabet Bucht</i>		<i>Masato Ikeda, Masayuki Ohmori, Toyoshi Endo and Toshimasa Onaya</i>	
Influence of smoking and snuff use on electrolytes, adrenal and calcium regulating hormones	35	Immunodetection of TSH receptor antibodies in sera of patients with autoimmune thyroid disease by ELISA (enzyme-linked immunosorbent assay)	126
<i>Armin E Heufelder, Bjoern E Wenzel and Rebecca S Bahn</i>		<i>Andrea Giustina, Mauro Doga, A Rosa Bussi, Massimo Licini and Maurizio Schettino</i>	
Glucocorticoids modulate the synthesis and expression of a 72 kDa heat shock protein in cultured Graves' retroocular fibroblasts	41	Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly	131
<i>D Sandrock, T Olbricht, D Emrich, G Benker and D Reinwein</i>		<i>Cindy A Harlin, James M Tucker, Cary L Winkler, Brenda Henson and Charles R Parker, Jr</i>	
Long-term follow-up in patients with autonomous thyroid adenoma	51	Altered adrenal steroid production in term infants having respiratory acidosis	136
<i>Gila Maor, Zeev Hochberg and Michael Silbermann</i>		<i>Cheryl A Conover, Gavin D Divertie and Phillip DK Lee</i>	
Insulin-like growth factor I accelerates proliferation and differentiation of cartilage progenitor cells in cultures of neonatal mandibular condyles	56	Cortisol increases plasma insulin-like growth factor binding protein-1 in humans	140
<i>Mimi H Chiang, Kevin M Kelley and Charles S Nicoll</i>		<i>Hannah Kanety, Avraham Karasik, Beatrice Klingler, Aviva Silbergeld and Zvi Laron</i>	
Human placental lactogen directly inhibits rat cartilage growth processes in vivo and in vitro	65	Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity	144
<i>Noritaka Takeshita, Hitoshi Ishida, Taizo Yamamoto, Gyohan Koh, Takeshi Kurose, Kazuo Tsuji, Yoshimasa Okamoto, Hitoshi Ikeda and Yutaka Seino</i>		<i>Paolo Limone, Valerio D'Alessandro, Innocenzo Rainero, Caterina Ambrogio, Lorenzo Pinessi, Tiziana De Gennaro and Gian Michele Molinatti</i>	
Circulating levels and bone contents of bone γ -carboxyglutamic acid-containing protein in rat models of non-insulin-dependent diabetes mellitus	69	Adrenergic regulation of α -MSH secretion in man: evidence for a stimulatory role of β -receptors	150
<i>Maria A Villanua, Agnieszka Szary, Ana I Esquifino and Andrzej Bartke</i>		<i>Brita Winsa, Agneta Mandahl and F Anders Karlsson</i>	
Thymostimulin effects on lymphoid organs in Ames dwarf mice	74	Graves' disease, endocrine ophthalmopathy and smoking	156
<i>Björn F Lindgren, Monica Isaksson, Ingrid Stern and Kerstin Hall</i>			
Insulin-like growth factor binding protein-1 from Hep G2 cells is potently inhibited by the truncated IGF-1 analogue des-(1-3) IGF-1	81		

MW Beckmann, P Wieacker, MM Dereser, U Flecken and M Breckwoldt		of measuring plasma NPY using antisera with different specificities	243
Influence of steroid hormones on 5 α -reductase activity in female and male genital skin fibroblasts in culture	161	<i>Per H Andersen, Bjørn Richelsen, Jens Bak, Ole Schmitz, Niels S Sørensen, Rodolphe Lavielle and Oluf Pedersen</i>	
<i>Tuulikki Nyman and Fredrika Pekonen</i>		Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients	251
The expression of insulin-like growth factors and their binding proteins in normal human lymphocytes	168	<i>Janice Rymer, David Crook, Mandeep Sidhu, Michael Chapman and John C Stevenson</i>	
<i>Franz Schwarzenberger, Geoffrey S Toole, Heather L Christie and James I Raeside</i>		Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women	259
Plasma levels of several androgens and estrogens from birth to puberty in male domestic pigs	173	<i>Henning K Nielsen, Bente Pedersen, Kim Brixen, Ronald Dahl and Peder Charles</i>	
<i>Gyorgy Nemezc and Eliklimi K Asem</i>		The effect of single doses of inhaled beclomethasone dipropionate on the circadian rhythm in serum osteocalcin in normals	263
Evidence for the presence of fatty acid binding protein in avian granulosa cells	178	<i>René Habert</i>	
<i>Bálint Kacsóh, Judith S Opp (Meyers), William R Crowley and Clark E Grosvenor</i>		In vivo acute testicular testosterone response to injection of luteinizing hormone in the rat fetus	268
Interaction between the α_2 -adrenergic system and nursing in the regulation of growth hormone secretion in the neonatal rat	184	<i>Carlo Foresta and Roberto Mioni</i>	
<i>Osamu Murakami, Kazuhiro Takahashi, Masahiko Sone, Kazuhito Totsune, Makoto Ohneda, Keiichi Itoi, Kaoru Yoshinaga and Torachi Mouri</i>		The role of calcium ions in rat Leydig cell steroidogenesis induced by atrial natriuretic peptide	274
An ACTH-secreting bronchial carcinoid: presence of corticotropin-releasing hormone, neuropeptide Y and endothelin-1 in the tumor tissue	192	<i>Manuela Simoni, Friedrich Jockenhövel and Eberhard Nieschlag</i>	
<i>Maria N Moreira-Andres, Francisco J Cañizo and Federico Hawkins</i>		Biological and immunological properties of the international standard for FSH 83/575: isoelectrofocusing profile and comparison with other FSH preparations	281
Is there a place for urinary growth hormone measurement?	197	<i>Maria João GM Bugalho, JF Moura Nunes, LG Sobrinho, E Medina, JA Martins Campos, C Gomes da Silva and Ana L Clode</i>	
<i>U Bogner, H-R Arntz, H Peters and H Schleusener</i>		Multihormonal response to CRH in a patient with Cushing syndrome and a pituitary adenoma producing ACTH and GH	289
Subclinical hypothyroidism and hyperlipoproteinaemia: indiscriminate L-thyroxine treatment not justified	202	<i>Nicoletta Sonino, Maria E Girelli, Marco Boscaro, Francesco Fallo, Benedetto Busnardo and Giovanni A Fava</i>	
<i>Susanne Lannig, Birger Thorsteinsson, Michael E Røder, Cathrine Ørskov, Jens J Holst, Jørn Nerup and Christian Koch</i>		Life events in the pathogenesis of Graves' disease. A controlled study	293
Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance	207	<i>Henrik Nordin, Anders M Galløe, Søren D Ladefoged and Jørn Badskjær</i>	
<i>Katsumi Eguchi, Atsushi Kawakami, Munetoshi Nakashima, Hiroaki Ida, Souko Sakito, Masahiro Sakui, Kaoru Terada, Yojiro Kawabe, Takaaki Fukuda, Naofumi Ishikawa, Kunihiko Ito and Shigenobu Nagataki</i>		The effects of propranolol and verapamil on hyperthyroid heart symptoms and function, assessed by systolic time intervals	297
Stimulation of mitogenesis in human thyroid epithelial cells by endothelin	215	<i>Anette Kvistborg, Johan Halse, Søren Bakke, Trine Bjørø, Egill Hansen, Ole Djøseland, Judith Brownell and Jak Jervell</i>	
<i>Michael Højby Rasmussen, Helle Carstensen, Søren List, Thue W Schwartz and Jannik Hilsted</i>		Long-term treatment of macroprolactinomas with CV 205-502	301
Impaired pancreatic polypeptide response to a meal in type 1 diabetic patients: vagal neuropathy or islet cell dysfunction?	221	<i>T Bjørø, E Johansen, HH Frey, A Turter and PA Torjesen</i>	
<i>Hiroya Matsuo, Takeshi Maruo, Kazuo Murata and Matsuo Mochizuki</i>		Different responses in little and bigbig prolactin to metoclopramide in subjects with hyperprolactinemia due to 150-170 kD (bigbig) prolactin	308
Human early placental trophoblasts produce an epidermal growth-factor-like substance in synergy with thyroid hormone	225	<i>Roman Deyssig, Herwig Frisch, Werner F Blum and Thomas Waldhör</i>	
<i>Per Hall, Göran Lundell and Lars-Erik Holm</i>		Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes	313
Mortality in patients treated for hyperthyroidism with iodine-131	230	<i>Hanno Pijl, Hans PF Koppeschaar, Frans LA Willekens, Marijke Frölich and A Edo Meinders</i>	
<i>Hirotaaka Shibata, Hiromichi Suzuki, Tadashi Ogishima, Yuzuru Ishimura and Takao Saruta</i>		The influence of serotonergic neurotransmission on pituitary hormone release in obese and non-obese females	319
Significance of steroidogenic enzymes in the pathogenesis of adrenal tumour	235	<i>Janet W McArthur, Barry A Turnbull, Jon Pehrson, Mary Bauman, Karen Henley, Adrian Turner, William J Evans, Beverly A Bullen and Gary S Skrinar</i>	
<i>Antoine Tabarin, Pierre Cassiède, Anne Perrot Minot, Jean Claude Cuber, Patrick Roger and Dominique Ducassou</i>		Nalmefene enhances LH secretion in a proportion of oligo-amenorrhic athletes	325
Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power		<i>K Devriendt, G Massa, F de Zegher, M Vanderschueren-Lodewyckx, JJ Cassiman, H Van den Berghe and P Marynen</i>	

Opposite effects of growth hormone and estrogens on the pregnancy zone protein serum levels in children and adolescents	334	<i>Gesche Tallen, Susanne Fehr, Wolfgang Saeger, Holger Uhlig and Dieter K Lüdecke</i>	Detection of growth hormone, prolactin and human β -chorionic gonadotropin mRNA in growth hormone-secreting pituitary adenomas and in prolactin-secreting pituitary adenomas by in situ hybridization using a non-isotopic detection method	411
<i>Eng-Cheng Chan, Roger Smith, Terry Lewin, Max W Brinsmead, Hong-Ping Zhang, Jeff Cubis, Kathryn Thornton and Di Hurt</i>			<i>Kerstin Landin, Björn Petruson, Karl-Erik Jakobsson and Bengt-Åke Bengtsson</i>	
Plasma corticotropin-releasing hormone, β -endorphin and cortisol inter-relationships during human pregnancy	339		Skeletal muscle sodium and potassium changes after successful surgery in acromegaly: relation to body composition, blood glucose, plasma insulin and blood pressure	418
<i>Luigi R Garibaldi, Thomas Aceto, Jr and Colleen Weber</i>			<i>Ove Tørring, Bengt Isberg, Hans Erik Sjöberg, Elisabet Bucht and Anna Lena Hulting</i>	
The pattern of gonadotropin and estradiol secretion in exaggerated thelarche	345		Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment	423
<i>Lise Duranteau, Philippe Chanson, Joelle Blumberg-Tick, Guy Thomas, Sylvie Brailly, Jean Lubetzki, Gilbert Schaison and Philippe Bouchard</i>			<i>Ad R Hermus, Gerlach F Pieters, George F Borm, Albert A Verhofstad, Anthony G Smals, Theo J Benraad and Peter W Kloppenborg</i>	
Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect	351		Unpredictable hypersecretion of cortisol in Cushing's disease: detection by daily salivary cortisol measurements	428
<i>Hiroyuki Kasumi, Shinji Komori, Noriyuki Yamasaki, Hiroki Shima and Shinzo Isojima</i>			<i>Bärbel Reichardt, Gerhard Mehlretter, Karin Lechner, Hans K Rjosk, Otto A Müller and Jochen Schopohl</i>	
Single nucleotide substitution of the androgen receptor gene in a case with receptor-positive androgen insensitivity syndrome (complete form)	355		Immunoreactive inhibin in human follicular fluid in an ovarian hyperstimulation programme for in vitro fertilization: correlations and different forms	433
<i>Marie Aanestad, J Sigurd Røtnes, Peter A Torjesen, Egil Haug, Olav Sand and Trine Bjøro</i>			<i>Luca Chiovato, Giuseppe Canale, Doretta Maccherini, Valeria Falcone, Furio Pacini and Aldo Pinchera</i>	
Epidermal growth factor stimulates the prolactin synthesis and secretion in rat pituitary cells in culture (GH ₄ C ₁ cells) by increasing the intracellular concentration of free calcium	361		<i>Salmonella brandenburg: a novel cause of acute suppurative thyroiditis</i>	439
<i>Chizu Nakamoto, Hisamitsu Baba, Masaaki Fukase, Kiichiro Nakajima, Terutoshi Kimura, Shumpei Sakakibara, Takuo Fujita and Kazuo Chihara</i>			<i>Joan M Zanelli, Rose E Gaines-Das and P Corran</i>	
Individual and combined effects of intact PTH, amino-terminal, and a series of truncated carboxyl-terminal PTH fragments on alkaline phosphatase activity in dexamethasone-treated rat osteoblastic osteosarcoma cells, ROS 17/2.8	367		Establishment of the second international standards for porcine and human calcitonins: report of the international collaborative study	443
<i>H-G Schneider, F Raue, A Koppold, W Ruf and R Ziegler</i>			<i>H Liang, O Morin and AG Burger</i>	
Homologous desensitization of calcitonin receptors and calcitonin-dependent adenylate cyclase in T47D cells	373		Effect of the antioxidant TK 12627 (Irganox) on monodeiodination and on the levels of messenger ribonucleic acid of 5'-deiodinase type I and spot 14	451
<i>Kentaro Yamada, Chizuko Inada, Shuichi Otabe, Naoko Takane, Hideki Hayashi and Kyohei Nonaka</i>			<i>Irving M Spitz, Oskari Heikinheimo and Charles W Wade</i>	
Effects of free radical scavengers on cytokine actions on islet cells	379		The divergent effect of RU 486 on adrenal function in the dog is related to differences in its pharmacokinetics	459
<i>Chin Hsu, Jau-Nan Lee, Mei-Ling Ho, Bi-Hwa Cheng, Pi-Hseuh Shirley Li and John Yuh-Lin Yu</i>			<i>Anne Priou, Charles Oliver and Michel Grino</i>	
The facilitatory effect of N-methyl-D-aspartate on sexual receptivity in female rats through GnRH release	385		In situ hybridization of arginine vasopressin (AVP) heteronuclear ribonucleic acid reveals increased AVP gene transcription in the rat hypothalamic paraventricular nucleus in response to emotional stress	466
<i>Pier Giorgio Chiodini, Roberto Attanasio, Renato Cozzi, Daniela Dallabonzana, Giuseppe Oppizzi, Paola Orlandi, Sonia Strada and Antonio Liuzzi</i>			<i>Christopher JH Woodward</i>	
CV 205-502 in acromegaly	389		A re-evaluation of the anabolic effect of testosterone in rats: interactions with gonadectomy, adrenalectomy and hypophysectomy	473
<i>Yoshikazu Nishi, Michi Kajiyama, Shinichiro Miyagawa, Mitsuhiro Fujiwara and Kazuko Hamamoto</i>			<i>MP de la Llosa-Hermier, C Fernandez, J Martal and C Hermier</i>	
Growth hormone therapy in achondroplasia	394		Potential role for arachidonic acid and eicosanoids in modulating progesterone secretion by ovine chorionic cells	478
<i>Peter Bang, Marie Degerblad, Marja Thorén, Jürg Schwander, Werner Blum and Kerstin Hall</i>			<i>Sandra Ceccatelli and Catello Orazzo</i>	
Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome	397		Effect of different types of stressors on peptide messenger ribonucleic acids in the hypothalamic paraventricular nucleus	485
<i>TH Jones, RL Kennedy, SK Justice and A Price</i>			<i>Yasunori Ozawa and Yoshimasa Shishiba</i>	
Interleukin-1 stimulates the release of interleukin-6 from cultured human pituitary adenoma cells	405		Recovery from lymphocytic hypophysitis associated with painless thyroiditis: clinical implications of circulating antipituitary antibodies	493

<i>A Paul Pickerill, Phillip F Watson, Nikhil Tandon and Anthony P Weetman</i>		<i>Eva Redei and Ellen W Freeman</i>	
T cell receptor β chain gene polymorphisms in Graves' disease	499	Preliminary evidence for plasma adrenocorticotropin levels as biological correlates of premenstrual symptoms	536
<i>Kozo Hashimoto, Tatsuya Nishioka, Yukiko Numata, Takashi Ogasa, Jingo Kageyama and Shuso Suemaru</i>		<i>Mikhail A Krasil'nikov, Valentina A Shatskaya, Zoiya V Kuzmina, Vladimir V Barinov, Victor P Letyagin and Laura S Bassalyk</i>	
Plasma levels of corticotropin-releasing hormone in hypothalamic-pituitary-adrenal disorders and chronic renal failure	503	Regulation of phospholipid turnover by steroid hormones in endometrial carcinoma and breast cancer cells	543
<i>BC Thomas, R Stanhope, PN Plowman and AD Leiper</i>		<i>James I Raeside, Chad R Wilkinson and Gabrielle Farkas</i>	
Endocrine function following single fraction and fractionated total body irradiation for bone marrow transplantation in childhood	508	Ontogenesis of estrogen secretion by porcine fetal testes	549
<i>Jens OL Jørgensen, Werner F Blum, Nanette Horn, Niels Møller, Jens Møller, Michael B Ranke and Jens S Christiansen</i>		<i>V Laurent-Cadoret, F Guillou and Y Combarrous</i>	
Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: studies in GH-deficient patients	513	Involvement of cAMP-dependent protein kinase isozymes in tissue plasminogen activator secretion by rat Sertoli cells stimulated with follicle-stimulating hormone in vitro	555
<i>Ali Iranmanesh, German Lizarralde and Johannes D Veldhuis</i>		<i>William Gibb and Robert Breton</i>	
Coordinate activation of the corticotropic axis by insulin-induced hypoglycemia: simultaneous estimates of β -endorphin, adrenocorticotropin, and cortisol secretion and disappearance in normal men	521	Studies on the action of dexamethasone on prostaglandin production by freshly dispersed amnion cells	563
<i>Takeshi Shimada, Keigo Yasuda, Akihiro Mori, Huiping Ni, Leilani B Mercado-Asis, Hiroshi Murase and Kiyoshi Miura</i>		<i>Lars Eikvar, Kristin A Taskén, Winnie Eskild and Vidar Hansson</i>	
Aldosterone binding to mineralocorticoid receptors of mononuclear leucocytes in diabetic subjects	529	Protein kinase C activation and positive and negative agonist regulation of 3', 5'-cyclic adenosine monophosphate levels in cultured rat Sertoli cells	568

Immunoreactive inhibin in human follicular fluid in an ovarian hyperstimulation programme for in vitro fertilization: correlations and different forms

Bärbel Reichardt, Gerhard Mehlretter, Karin Lechner, Hans K Rjosk, Otto A Müller and Jochen Schopohl

Medizinische Klinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität München; Gynäkologische Gemeinschaftspraxis¹; Krankenanstalten Rotes Kreuz; München, Germany

Reichardt B, Mehlretter G, Lechner K, Rjosk HK, Müller OA, Schopohl J. Immunoreactive inhibin in human follicular fluid in an ovarian hyperstimulation programme for in vitro fertilization: correlations and different forms. *Acta Endocrinol* 1993;128:433-8. ISSN 0001-5598

The inhibin concentration in 131 samples of human follicular fluid obtained from 31 women undergoing ovarian hyperstimulation for in vitro fertilization was measured using specific double antibody radioimmunoassay. We used the synthetic 1-32- α -inhibin as standard and radioiodinated 1-32-Tyr- α -inhibin as tracer. Antibodies were raised in rabbits by immunization with the synthetic peptide. Estradiol and progesterone concentrations were measured using commercial radioimmunoassays. **Results:** The inhibin concentration correlated with the estradiol ($r=0.57$, $N=88$, $p<0.0001$) and progesterone ($r=0.82$, $N=88$, $p<0.0001$) concentrations in human follicular fluid. The dosage of human menopausal gonadotropin given to individual patients correlated with the average inhibin concentration measured in their follicles ($r=0.72$, $N=23$, $p<0.0001$). Similarly, the size of follicles correlated with their inhibin content ($r=0.75$, $N=131$, $p<0.0001$). Nineteen samples of human follicular fluid originating from follicles of different size and volume were examined using gel-chromatography. In each human follicular fluid the main form of inhibin (32 kDa) was recovered. In small follicles (3 ml) we found $12.8 \pm 9.1\%$ (mean \pm SD) of the whole immunoreactive inhibin eluting in the area of V_0 (≥ 80 kDa). In the larger follicles (4-7 ml), however, only $4.4 \pm 4.2\%$ of this large inhibin form could be found. **Conclusions:** Our data confirm that human menopausal gonadotropin stimulates ovarian inhibin production. In addition to the estradiol and progesterone concentrations, the inhibin concentration may be an index of granulosa cell function and follicular maturation. The occurrence of large molecular weight forms of inhibin in small follicles remains unclear. They may represent large precursor molecules which are proteolytically cleaved in more mature follicles.

Jochen Schopohl, Medizinische Klinik, Klinikum Innenstadt, Ziemssenstr. 1, W-8000 München 2, Germany

Inhibin is a gonadal glycoprotein which selectively suppresses FSH-mRNA production and secretion of FSH, but not of LH, from the pituitary gland (1, 2). Since inhibin was purified in 1985 (3, 4) its detection has been limited to bioassays (5, 6) and several heterologous radioimmunoassays (RIA) using antibodies against 58 kDa or 32 kDa inhibin isolated from bovine follicular fluid (7).

There are at least two biologically active inhibin molecules, named inhibin A (α - β_A) and inhibin B (α - β_B) (8), being members of a large family which includes activin, transforming growth factor β (TGF β) and Müllerian inhibiting substance (8).

Furthermore, the amino acid sequence of both subunits of inhibin and their precursors have been analyzed and the existence of multiple molecular weight forms of inhibin in bovine follicular fluids have been demonstrated (9, 10). Dynamic changes in the different molecular form of inhibin may also play a physiologically significant role in the regulation of FSH secretion and maturation of oocytes.

In this study we describe the development of a

heterologous RIA for human inhibin based on a synthetic peptide prepared from a sequence of the human inhibin α -chain. We studied human follicular fluids (hFF), derived from in vitro fertilization (IVF) patients to clarify different inhibin levels and molecular weight forms depending on follicle size, its stimulation with human menopausal gonadotropin (HMG) and the maturation of the oocyte.

Materials and methods

Patients

This study includes 131 hFF samples of 31 women (mean age 30.5 years, range 26 to 36) participating in an IVF programme. Most of the patients had regular ovulatory cycles as judged by basal body temperature charts and serum progesterone values. They were fully investigated by hysterosalpingography and the infertility was principally due to a tubal factor.

The stimulation of multiple follicles was initiated on the third cycle day by giving HMG ("Humegon",

Organon, Germany) 150–450 IU im daily. From the eighth cycle day onwards follicular growth was assessed by daily measurement of plasma estradiol and progesterone and by vaginal ultrasonography using a 5.0 MHz transducer (Kretz, Austria). Human chorionic gonadotropin (HCG, "Pregnyl", Organon, Germany) 10 000 IU im was given to the patients to induce ovulation when the mean diameter of the largest follicle reached 15–17 mm. Oocyte pick-up was performed approximately 35 h after HCG injection by means of ultrasonically guided transvaginal follicular puncture. Oocytes were classified as degenerated, pre-mature and mature according to appearance of the cumulus-oocyte complex as described by Krebs and Al-Hasani (11). All oocytes were inseminated with husband sperm 2–6 h after aspiration. Sperm preparation was performed with a swim-up technique or Percoll density-gradient centrifugation. The oocytes were cultured in growth media and up to three embryos were transferred to the patients at the 2–6 cell stage approximately 40 h after insemination.

We used only hFFs without the addition of follicular rinsing fluid. All hFFs were centrifuged at $1400 \times g$ for 10 min to remove cellular fragments and blood cells and kept frozen at -18°C until further investigations. The experiments were in accordance with the ethical methods of the responsible committee on human experimentation and with the Helsinki Declaration.

Inhibin-RIA

The inhibin immunoreactivity was measured by specific double antibody RIA using an antibody directed against human inhibin- α -1-32, a synthetic fragment derived from the NH_2 -terminal sequence of the human α -subunit (Peninsula Lab., UK). Antibodies were raised in two male rabbits by monthly immunization with the synthetic peptide (1–32) coupled to bovine thyroglobulin according to the carbodiimide method (12). The resulting antiserum was used in a final dilution of 1:2000.

This synthetic fragment of human α -chain was also applied as standard. The radiotracer used in the RIA was human 1-32-Tyr- α -inhibin which had been labelled with ^{125}I on the terminal tyrosine by the iodogen method (13).

The incubation volume consisted of 0.1 ml antibody and 0.1 ml standard or unknown. Preincubation was carried out at 4°C over 24 h. After one day tracer incubation bound-free separation was performed using the double antibody PEG method.

The non-specific binding was less than 5% and tracer binding 15 to 20%. The ED_{50} of the standard curve was 0.05 nmol/l and the minimum detectable dose of inhibin found in the assay was 0.011 nmol/l.

Duplicate aliquots of each sample were assayed and the inter- and intra-assay coefficients of variation were 11.5% and 7.5% respectively. There was no cross-reaction with LH (500 U/l), HCG (200 U/l), FSH (500 U/l), porcine (7.8 nmol/l) and bovine inhibin




Fig. 1. Displacement curve of recombinant human inhibin A (—●—) in comparison to the standard curve with α -inhibin 1-32 (—○—, $x \pm \text{SD}$) and unpurified hFF (—▲—).

(15.6 nmol/l), inhibin-like peptide (20 nmol/l) or with activin (50 nmol/l) and TGF- β (100 nmol/l). Displacement curves of several pools of unpurified hFF and recombinant human inhibin A in this RIA were parallel to that of the 1-32- α -inhibin standard (Fig. 1). Recombinant human inhibin A was a gift from Dr Schwall, Genentech, CA.

Estradiol and progesterone assay

In addition to inhibin, estradiol (E_2) and progesterone (P) concentrations were measured in the same samples by RIA using commercially available kits (Baxter). Because of the high concentration of steroids in hFF the samples were diluted 1:1000 in E_2 -free and P-free serum before measurement.

Gel chromatography by Sephadex G-75

Gel chromatography was performed using a column of 1×60 cm with Sephadex G-75 (Pharmacia), prepared and evaluated as described in the users' manual of Pharmacia. The elution buffer contained 0.1 mol/l acetic acid with 0.1% BSA.

Statistical analysis

Correlations between the measured variables were tested by *t*-distribution. Correlation between the maturity of the oocytes and inhibin content of the hFFs was performed using the Mann-Whitney U-test.




Fig. 2. Correlation between concentration of α -inhibin 1-32 and estradiol measured in human follicles ($r=0.57$, $N=88$, $p<0.0001$).




Fig. 3. Correlation between concentration of α -inhibin 1-32 and progesterone measured in human follicles ($r=0.82$, $N=88$, $p<0.0001$).

Results

A positive correlation was found between the size of 131 human follicles and their inhibin content, obtained from 31 IVF patients ($r=0.75$, $N=131$, $p<0.0001$). The follicles varied in size from 1 to 7 ml, according to the content of hFF.

The dosage of exogenous FSH, given as daily HMG injections to individual patients to stimulate follicular growth, correlated with the average inhibin concentration measured in their follicles ($r=0.72$, $N=23$, $p<0.0001$).

The inhibin concentration correlated with the E_2 concentration ($r=0.57$, $N=88$, $p<0.0001$) in 88 samples of hFF derived from 26 women undergoing IVF treatment (Fig. 2). A positive correlation was also found between the inhibin and P concentration ($r=0.82$,

$N=88$, $p<0.0001$) in the same 88 hFFs obtained from the same 26 IVF patients (Fig. 3).

The inhibin content of 88 hFF of 26 IVF patients was analysed in comparison to the maturity of the according oocyte (11). In follicles with a mature oocyte we found a lower inhibin content (0.013 nmol) than in follicles having a degenerated or immature oocyte (0.023 nmol, $p<0.005$).

We examined 19 samples of hFF of 6 IVF patients by gel chromatography using a Sephadex G-75 column. These hFFs originated from follicles of different size and volume (3–7 ml). Recovery after chromatography was about 90%. In each hFF we found a peak with a distribution coefficient (K_d) of 0.34, representing the main inhibin form of 32 kDa. In small follicles with a volume of 3 ml we found a second peak in the area of V_0 (K_d 0–0.08), where 12.8 \pm 9.1% of the whole immunoreactive inhibin was recovered ($N=6$). In contrast, in the larger follicles (4–7 ml) we found only 4.4 \pm 4.2% of inhibin eluting with the void volume ($N=13$), shown in Figs. 4, 5 and Table 1. Dilutions of both peaks were parallel to the slope of the standard curve of α -inhibin 1–32. The molecular mass of both peaks exceeded 22 kDa, indicating that there are no isolated α -chains (18 kDa) found in hFF.

Discussion

We describe the development of an inhibin RIA, based on an available 1–32 peptide of the human α -chain of inhibin, demonstrating that this assay measures inhibin in native follicular fluid and recombinant human inhibin A, as shown in the displacement curves (Fig. 1).

Sinosich et al. (14) developed a similar homologous RIA based on the cyclic synthetic peptide 6-30- α -inhibin, whereas Franchimont et al. (15) used 5-24- α -inhibin to measure inhibin.

In comparison to heterologous assay designs (7), using polyclonal antisera raised in rabbits against purified bovine inhibin, our RIA recognizes only the α -chain of human inhibin and does not show any cross-reaction with porcine or bovine inhibin or other members of the inhibin family, e.g. activin or TGF β .

Our assay probably recognizes not only the most bioactive 32 kDa form of human inhibin, but also a range of higher molecular weight forms (120, 108, 88, 65 and 58 kDa) that have been identified in bovine follicular fluid using monoclonal antibodies specific for each subunit (20 and 13 kDa) of bovine follicular fluid 32 kDa inhibin (9).

The occurrence of larger molecular weight forms (≥ 80 kDa) of inhibin in small follicles (3 ml) is unclear. Many polypeptide hormones are generated by the cleavage of larger precursor molecules and most precursors are unable to exert their full activity until they are processed to mature forms. It may be speculated that these larger forms of inhibin represent large precursor molecules (16, 17, 9) which are proteolytically cleaved in the more mature follicles (> 4 ml). Miyamoto et al. (9)




Fig. 4. Gel chromatography of two hFFs obtained from follicles of 6 ml (—□—) and 7 ml (—●—) using a Sephadex G-75 (1 × 60 cm) column. For each chromatography 1.5 ml of hFF was applied on the column; the fraction size was 1.25 ml.




Fig. 5. Gel chromatography of an hFF obtained from a follicle of 3 ml (—●—) using a Sephadex G-75 (1 × 60 cm) column.

Table 1. Percentage of the whole immunoreactive inhibin eluting in the area of V_0 depending on the size of the follicles (Figs 4, 5). Most of the immunoreactive inhibin eluates at a Kd of 0.34 corresponding to a molecular weight of 32 kDa.

Follicular size	6–7 ml	5 ml	4 ml	3 ml
	1.3%	7.3%	1.2%	7.3%
	2.5%	5.8%	0.0%	13.9%
	0.0%	2.9%	11.5%	9.6%
		12.6%	2.9%	24.1%
		7.0%	2.0%	0.0%
				21.7%
No. of samples	3	5	5	6
Mean (%)	1.3%	7.1%	3.5%	12.8%
SD±	1.2	3.5	4.6	9.1

suggested that at least the intact 32 kDa inhibin composed of 20 kDa and 13 kDa inhibin subunit linked by disulphide bridges is essential for inhibin activity and—as shown in our experiments—probably necessary for the maturing processes of the oocyte.

The hFF of the preovulatory follicle contains steroid and peptide factors that exert paracrine and autocrine control on maturation of the antral follicle (18), specifically of the oocyte-corona-cumulus complex (19). In normal and hyperstimulated ovulatory cycles the hFF content of E_2 and P as markers of granulosa cell function and follicular maturity is well established (19–21).

This study demonstrates that in the late follicular phase there is a positive correlation between inhibin, E_2 and P concentration in hFF (Figs. 2, 3). A positive

correlation has been found between serum inhibin and E_2 concentration during the follicular phase after hyperstimulation (21) and in the normal human menstrual cycle (22). We found that larger follicles contain more inhibin than smaller ones, probably because the inhibin secretory potential increases with the number of granulosa cells in larger follicles. Tsuchiya et al. (23) also expected the amount of circulating basal inhibin being secreted to be in correlation with the number of granulosa cells. We confirm that inhibin—besides E_2 and P—may be a valid index of granulosa cell function and follicular development during the hyperstimulation cycle.

This study shows that in response to ovarian hyperstimulation by exogenous HMG there is an increase in production of human ovarian inhibin. This stimulation of inhibin by HMG, which contains equal amounts of FSH and LH, is probably mediated by LH and FSH together, because it has recently been shown that LH stimulates inhibin production in human granulosa cells as well as FSH (24, 25). According to McLachlan et al. (26) and Bicsak et al. (27) our finding confirms that inhibin is a follicular product under FSH control, with granulosa cells playing the main role of production (16, 28).

Our findings of significantly lower inhibin levels in follicular fluids with mature oocytes in comparison with those with degenerated oocytes are not yet understood. Rising inhibin levels in serum (21) and follicular fluid during hyperstimulation have raised the possibility of using inhibin responses to ovarian hyperstimulation as an index of outcome in IVF and embryo transfer (26). Franchimont et al. (15) investigated inhibin levels in follicular fluid and concluded that inhibin appears to be an index of follicular maturation, since the inhibin content of follicles characterized as immature by their E_2/P ratios and E_2 is lower than that of mature follicles. These divergent statements may seem surprising, but in contrast to Franchimont et al., who classified the maturity of the oocyte by measuring E_2 and P in follicular fluid, we used the microscopic analysis of Al-Hasani (11) to characterize the oocyte and its grade of maturation. Because of these different kinds of classification a comparison of the opposing results is not appropriate.

No significant positive correlation could be found between follicular size and maturation grade of the oocyte. Larger follicles containing more inhibin do not necessarily indicate that the oocyte is mature. In larger follicles we found mainly the high bioactive 32 kDa inhibin (Fig. 4)—follicular fluid with mature oocytes may contain less higher molecular weight forms of inhibin but more 32 kDa inhibin.

A reduced inhibin production in very mature follicles indicates the luteinization of granulosa cells induced by HCG injection (29). We propose that a follicle with high inhibin levels might be too much hyperstimulated or does not luteinize by HCG injection.

Acknowledgments. We gratefully acknowledge Mr E Kreuzer and Mrs E Schaller for sampling the hFFs and for their help in discussing the results.

References

1. Carroll RS, Corrigan AZ, Gharib SD, Vale W, Chin WW. Inhibin, activin and follistatin: regulation of follicle-stimulating hormone messenger ribonucleic acid levels. *Mol Endocrinol* 1989;3:1969–76
2. Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35000 monomeric protein that inhibits the release of follicle-stimulating hormone. *Proc Natl Acad Sci USA* 1987;84:8282–6
3. Robertson DM, Foulds LM, Leversha L, Morgan FJ, Hearn MT, Burger HG, et al. Isolation of inhibin from bovine follicular fluid. *Biochem Biophys Res Commun* 1985;126:220–6
4. Rivier J, Spiess J, McClintock R, Vaughan J, Vale W. Purification and partial characterization of inhibin from porcine follicular fluid. *Biochem Biophys Res Commun* 1985;133:120–7
5. Michel U, Jarry H, Metten M, Wuttke W. Inhibin production by porcine granulosa and luteal cells: development and biological validation of a RIA. *Acta Endocrinol* 1989;120:511–18
6. Scott RS, Burger HG, Quigg H. A simple and rapid in vitro bioassay for inhibin. *Endocrinology* 1980;107:1536–42
7. McLachlan RI, Robertson DM, Burger HG, de Kretser DM. The radioimmunoassay of bovine and human follicular fluid and serum inhibin. *Molec Cell Endocrinol* 1986;46:175–85
8. Franchimont P, Hazeé-Hagelstein MT, Jaspard JM, Charlet-Renard C, Demoulin A. Inhibin and related peptides: mechanisms of action and regulation of secretion. *J Steroid Biochem* 1989;32:193–7
9. Miyamoto K, Hasegawa Y, Fukada M, Igarashi M. Demonstration of high molecular weight forms of inhibin in bovine follicular fluid (bFF) by using monoclonal antibodies to bFF 32K inhibin. *Biochem Biophys Res Commun* 1986;136:1103–9
10. Sugino K, Nakamura T, Takio K, Miyamoto K, Hasegawa Y, Igarashi M, et al. Purification and characterization of high molecular weight forms of inhibin from bovine follicular fluid. *Endocrinology* 1992;130:789–96
11. Krebs D, Al-Hasani S. *Praktikum der extrakorporalen Befruchtung*. Urban Schwarzenberg, 1984:109–12
12. Stalla GK, Giesemann G, Müller OA, Wood WG, Scriba PC. The development of a direct homologous radioimmunoassay for serum cortisol. *J Clin Chem Biochem* 1981;19:427–34
13. Salacinski PRP, McLean C, Sykes JEC, Clement-Jones VV, Lowry PJ. Jodination of proteins, glycoproteins and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 α ,6 α -diphenyl-glycoluril (Jodogen). *Anal Biochem* 1981;117:136–46
14. Sinosich MJ, Sieg S, Ling N, Saunders DM, Rosewaks Z, Hodgen GD. Radioimmunoassay of inhibin based on synthetic human α -chain peptide. *Clin Chem* 1991;37:40–6
15. Franchimont P, Hazeé-Hagelstein MT, Charlet-Renard C, Jaspard JM, Hazout A, Salat-Baroux J, et al. Correlation between follicular fluid content and the results of in vitro fertilization and embryo transfer. Inhibin and aromatase inhibitor activity. *J Clin Endocrinol Metab* 1990;71:748–54
16. Bicsak TA, Cajander SB, Vale W, Hsueh AJW. Inhibin: studies of stored and secreted forms by biosynthetic labeling and immunodetection in cultured rat granulosa cells. *Endocrinology* 1988;122:741–8
17. Ying SY, Ling N, Guillemin R. Inhibins and activins. *Ann NY Acad Sci* 1988;541:143–52
18. Franchimont P, Demoulin A, Valcke JC. Endocrine, paracrine and autocrine control of follicular development. *Horm Metab Res* 1988;20:193–203
19. Kreiner D, Hung-Ching L, Itskovitz, J, Veeck L, Rosenwaks Z. Follicular fluid estradiol and progesterone are markers of preovulatory oocyte quality. *Fertil Steril* 1987;48:991–4

20. Bomsel-Helmreich O, Cougeon A, Thebould A, et al. Healthy and atretic human follicles in the preovulatory phase: differences in evolution of follicular morphology and steroid content of follicular fluid. *J Clin Endocrinol Metab* 1979;48:686-94
21. Hughes EG, Robertson DM, Handelsman DJ, Hayward S, Healy DL, de Kretser DM. Inhibin and estradiol responses to ovarian hyperstimulation: effects of age and predictive value for in vitro fertilization outcome. *J Clin Endocrinol Metab* 1990;70:358-64
22. McLachlan RI, Robertson DM, Healy DL, Burger HG, de Kretser DM. Circulating immunoreactive inhibin levels during the normal human menstrual cycle. *J Clin Endocrinol Metab* 1987;65:954-61
23. Tsuchiya K, Seki M, Itoh M, Hasegawa Y, Miyamoto K, Igarashi M. Correlation of serum inhibin concentrations with results in an ovarian hyperstimulation program. *Fertil Steril* 1989;52:88-94
24. Hillier SG, Wickings EJ, Illingworth PJ, Yong EL, et al. Control of immunoreactive inhibin production by granulosa cells. *Clin Endocrinol* 1991;35:71-8
25. Illingworth PJ, Reddi K, Smith KB, Baird DT. The source of inhibin secretion during the human menstrual cycle. *J Clin Endocrinol Metab* 1991;73:667-73
26. McLachlan RI, Robertson DM, Healy DL, de Kretser DM, Burger HG. Plasma inhibin levels during gonadotropin-induced ovarian hyperstimulation for IVF: a new index of follicular function? *Lancet* 1986;i:1233-4
27. Bicsak TA, Tucker EM, Cappel S, Vaughan J, Rivier J, Vale W, et al. Hormonal regulation of granulosa cell inhibin biosynthesis. *Endocrinology* 1986;119:2711-19
28. Erikson GF, Hsuek AJW. Secretion of inhibin by rat granulosa cells in vitro. *Endocrinology* 1978;103:1960-3
29. Tsonis CG, Messinis IE, Templeton AA, McNeilly AS, Baird DT. Gonadotropic stimulation of inhibin secretion by the human ovary during the follicular and early luteal phase of the cycle. *J Clin Endocrinol Metab* 1988;66:915-21

Received September 23rd, 1992

Accepted January 16th, 1993